Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study

Levonadifloxacin is a novel broad-spectrum anti-MRSA agents belonging to the benzoquinolizine subclass of quinolone. It is developed for oral or intravenous administration for the treatment of infections caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA)....

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the Association of Physicians of India 2020-08, Vol.68 (8), p.30-36
Hauptverfasser:	Bhatia, A, Mastim, M, Shah, M, Gutte, R, Joshi, P, Kumbhar, D, Periasamy, H, Palwe, S R, Chavan, R, Bhagwat, S, Patel, M, Llorens, L, Friedland, H D
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Anti-Bacterial Agents - therapeutic use Fluoroquinolones - therapeutic use Humans India Linezolid Methicillin-Resistant Staphylococcus aureus - drug effects Staphylococcal Infections - drug therapy Staphylococcus aureus Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!